News
11h
Clinical Trials Arena on MSNMTPA’s Radicava shows long-term benefit in ALS trials
"MTPA’s Radicava shows long-term benefit in ALS trials" was originally created and published by Clinical Trials Arena, a ...
The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...
1d
Ansa on MSNItalo-US team in ALS diagnosis breakthrough
ROME, AUG 19 - An Italo-US team of scientists have made a breakthrough in the early diagnosis of amyotrophic lateral ...
Summary: A new study has uncovered why some motor neurons resist degeneration in ALS while others succumb. Researchers found ...
Jodi O’Donnell-Ames founded Hope Loves Company to provide support, resources, and community to children affected by ALS.
By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...
David Crean, Chief Business Officer at MediciNova (Nasdaq: MNOV), a late-stage, global biopharmaceutical company that is ...
Brooke Eby posted a "dying diary" to describe the feeling of her ALS and progressing paralysis. The 36-year-old TikToker ...
• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results